

**REMARKS**

This amendment under 37 CFR 1.312 is being filed concurrently with payment of the issue fee.

Applicants thank the Examiner for courtesies extended to Applicants' representative, Katharine Davis Wong, in the telephone conference of June 7, 2006. The Examiner acknowledged the typographical errors in the Notice of Allowability and advised Applicants to file an amendment under 37 CFR 1.312 to formally correct said errors.


In the Notice of Allowability mailed on May 24, 2006, the Examiner indicated that the allowed claims are 1 and 36-43. However, Applicants respectfully note that original claims 2-38 were cancelled and claims 39-46 were added during prosecution of the instant application, thus the allowed claims should be indicated as 1 and 39-46 and re-numbered as 1-9, respectively.

Applicants respectfully submit that the amendment to claim 39 (re-numbered as claim 2) made herein is for correction of an inadvertent typographical error only and requires no additional search or examination. In the Examiner's amendment to claim 39 the phrase "which is linked to insulin resistance" was inserted after "SEQ ID NO:2". However, since the claim recites three sequence identification (SEQ ID NOS:1-3) numbers the phrase should be inserted after "SEQ ID NO:3".

**CONCLUSION**

Applicants respectfully request favorable consideration of the instant amendment followed with issuance of the above-referenced application as a US Patent.

Respectfully submitted,

  
\_\_\_\_\_  
Ferris H. Lander  
Registration # 43,377

McHale & Slavin, P.A.  
2855 PGA Boulevard  
Palm Beach Gardens, FL 33410  
(561) 625-6575 (Voice)  
(561) 625-6572 (Fax)

\\Ns2\SERVER\CLIENT FILES\2100-2199\2132 -Syn-X\2132\_000102 - Complement C3 Precursor  
Biopolymer\Amendments\2132\_102\_312\_Amend\_kfdw.wpd